Center-Authored Papers

Filters: First Letter Of Keyword is P  [Clear All Filters]
A B C D E F G H I J K L M N O [P] Q R S T U V W X Y Z   [Show ALL]
Pyrrolidines
Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, Goldstein S, Sriram U, Lee A, Thompson J et al..  2010.  Lasofoxifene in postmenopausal women with osteoporosis.. The New England journal of medicine. 362(8):686-96. Abstract
Ensrud K, LaCroix AZ, Thompson JR, Thompson DD, Eastell R, Reid DM, Vukicevic S, Cauley J, Barrett-Connor E, Armstrong R et al..  2010.  Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial.. Circulation. 122(17):1716-24. Abstract
LaCroix AZ, Powles T, Osborne KC, Wolter K, Thompson JR, Thompson DD, Allred CD, Armstrong R, Cummings SR, Eastell R et al..  2010.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.. Journal of the National Cancer Institute. 102(22):1706-15. Abstract
LaCroix AZ, Powles T, Osborne KC, Wolter K, Thompson JR, Thompson DD, Allred CD, Armstrong R, Cummings SR, Eastell R et al..  2010.  Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women.. Journal of the National Cancer Institute. 102(22):1706-15. Abstract
Pyrroles
Ramsey SD, Clarke LD, Roberts CS, Sullivan SD, Johnson SJ, Liu LZ.  2008.  An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.. PharmacoEconomics. 26(4):329-39. Abstract
Hansen RN, Hackshaw MD, Sullivan SD, Ramsey SD.  2015.  The Authors Respond.. Journal of managed care & specialty pharmacy. 21(9):844.
Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, Bauman JE, Martins RG.  2010.  Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.. Clinical cancer research : an official journal of the American Association for Cancer Research. 16(21):5260-8. Abstract
Hartwell LH, MAGASANIK B.  1964.  THE MECHANISM OF HISTIDASE INDUCTION AND FORMATION IN BACILLUS SUBTILIS.. Journal of molecular biology. 10:105-19.
Pyrophosphatases
Fishburn J, Hahn S.  2012.  Architecture of the yeast RNA polymerase II open complex and regulation of activity by TFIIF.. Molecular and cellular biology. 32(1):25. Abstract
Pyrimidines
Chew HK, Barlow WE, Albain K, Lew D, Gown A, Hayes DF, Gralow JR, Hortobagyi GN, Livingston R.  2008.  A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.. Clinical breast cancer. 8(6):511-5. Abstract
Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin M-E, Taub JM, Herman B, Higano CS et al..  2015.  Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 56(3):354-60. Abstract
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F et al..  2009.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(35):6041-51. Abstract
Chen GL, Arai S, Flowers MED, Otani JM, Qiu J, Cheng EC, McMillan A, Johnston LJ, Shizuru JA, Miklos DB.  2011.  A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.. Blood. 118(15):4070-4078. Abstract
Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury JH, Khoroshko N et al..  2009.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.. Blood. 113(25):6322-9. Abstract
Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M et al..  2009.  Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(6):1054-61. Abstract
Radich JP.  2012.  Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.. Cancer. 118(2):300-11. Abstract
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract
Kim DHD' ', Sriharsha L, Jung CW, Kamel-Reid S, Radich JP, Lipton JH.  2010.  Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: which parameter at which time-point does matter? American journal of hematology. 85(11):856-62. Abstract
Hochhaus A, Müller MC, Radich JP, Branford S, Kantarjian HM, Hanfstein B, Rousselot P, Kim D-W, Lipton JH, Bleickardt E et al..  2009.  Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.. Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K. 23(9):1628-33. Abstract
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F et al..  2013.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.. Blood. 122(6):872-84. Abstract
Somlo G, Atzori F, Strauss LC, Geese WJ, Specht JM, Gradishar WJ, Rybicki A, Sy O, Vahdat LT, Cortes J.  2013.  Dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase I study CA180004.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(7):1884-93. Abstract
Cortes JE, Kantarjian HM, Goldberg SL, Powell BL, Giles FJ, Wetzler M, Akard L, Burke JM, Kerr R, Saleh M et al..  2009.  High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(28):4754-9. Abstract
Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP et al..  2011.  SHP1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.. Blood. 118(13):3634-44. Abstract
Hansen RN, Hackshaw MD, Sullivan SD, Ramsey SD.  2015.  The Authors Respond.. Journal of managed care & specialty pharmacy. 21(9):844.
Woodahl EL, Wang J, Heimfeld S, Ren AG, McCune JS.  2008.  Imatinib inhibition of fludarabine uptake in T-lymphocytes.. Cancer chemotherapy and pharmacology. 62(4):735-9. Abstract